Truist Financial Issues Positive Forecast for Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price

Amneal Pharmaceuticals (NASDAQ:AMRX) had its price target lifted by research analysts at Truist Financial from $15.00 to $17.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s target price points to a potential upside of 23.10% from the company’s current price.

A number of other research firms have also recently commented on AMRX. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Barclays assumed coverage on Amneal Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $15.00 price target on the stock. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $14.20.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock opened at $13.81 on Monday. The company has a market capitalization of $4.34 billion, a PE ratio of 60.05 and a beta of 1.36. The firm’s 50-day moving average is $13.74 and its two-hundred day moving average is $11.76. Amneal Pharmaceuticals has a 12 month low of $6.68 and a 12 month high of $15.42.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Spire Wealth Management increased its stake in Amneal Pharmaceuticals by 66.6% during the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after purchasing an additional 1,023 shares during the period. Intech Investment Management LLC grew its holdings in shares of Amneal Pharmaceuticals by 1.2% in the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock valued at $1,229,000 after purchasing an additional 1,159 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Amneal Pharmaceuticals by 2.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after buying an additional 1,582 shares during the period. Comerica Bank lifted its holdings in Amneal Pharmaceuticals by 56.1% during the 4th quarter. Comerica Bank now owns 4,690 shares of the company’s stock worth $59,000 after buying an additional 1,685 shares in the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in Amneal Pharmaceuticals in the 4th quarter valued at approximately $26,000. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.